Open Tender Watch
Menu v
ACCESS EN PT
← Companies Company PT

SANOFI - PRODUTOS FARMACÊUTICOS, LDA

NIF 500134960
↓ CSV ↓ JSON
Risk Flags
A1 · Repeat Direct Award €74,895,728 138 contracts
Same supplier receives ≥2 direct awards in 36 months with cumulative value above the CCP Art. 113 §2 statutory cap
HIGH €74,895,728 138 contracts
A2 · Late Publication €17,905,217,535 5,600 contracts
Contract published to BASE more than 10 days after the signing date
LOW €17,905,217,535 5,600 contracts
A5 · Threshold Splitting €40,507,335 181 contracts
Contract value falls within 5% below a procedural threshold (€5K / €20K / €75K / €150K / €5.35M). Score: 35 · Severity: Medium.
HIGH €40,507,335 181 contracts
A6 · Low Competition €507,955,997 167 contracts
Only one bidder participated in a competitive procedure
MEDIUM €507,955,997 167 contracts
A9 · Price Overrun €73,764 7 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
HIGH €73,764 7 contracts
A9 · Abnormal Price Reduction €23,235,325,304 2,704 contracts
Effective price exceeds base price by >50% (score 30) or >100% (score 55); or effective price is <50% of base (score 10, possible predatory bid or data error). Severity: Medium/High/Low.
LOW €23,235,325,304 2,704 contracts
C3 · Missing Mandatory Fields €14,326,185 119 contracts
CPV code, procedure type, or base price absent for the procedure type, or base price exceeds ±€1 trillion (implausible data entry). Score: 20 · Severity: Low.
LOW €14,326,185 119 contracts

Procurement Network

Aggregated links between this entity and connected counterparties

Public view excludes person-level links and tax identifiers.

Loading network…
Legend Focus entity Public body Company Anonymized individual

Contracts by Contracting Authority

335
€1,312,432,947
65
€1,112,172,483
527
€974,909,583
332
€934,480,965
151
€925,670,211
39
€818,516,811
628
€774,629,736
58
€730,416,588
410
€704,702,952
85
€692,263,962
74
€671,905,157
62
€653,576,073
104
€635,987,675
109
€623,649,496
91
€608,544,587
52
€607,357,024
78
€559,213,855
80
€551,428,223
68
€539,506,031
120
€527,792,680
Page 1 of 4 · 78 authorities
Next →

All Contracts Won

Signal: All A1 · Repeat Direct Award A2 · Late Publication A5 · Threshold Splitting A6 · Low Competition A9 · Price Overrun A9 · Abnormal Price Reduction C3 · Missing Mandatory Fields

Page 1 of 1 · 7 contracts

Medicamentos
PT · 994c6ca5a310bf66de2b · Ajuste Direto Regime G...
A2 · Late Publication A9 · Price Overrun
€254 2025-06-12
Aprov/PRT 22001202 - AP 643
PT · 9375886 · Ao abrigo de acordo-qu...
A9 · Price Overrun
€50 2022-07-11
Imiglucerase 400 U Pó conc sol inj Fr IV
PT · 2999906 · Ao abrigo de acordo-qu...
A9 · Price Overrun A2 · Late Publication
€45,603 2017-01-18
Medicamentos
PT · 5a55de0af3d58a0d3352 · Ajuste direto
A2 · Late Publication A9 · Price Overrun
€11 2014-12-19
CABAZITAXEL
PT · 8effecd0c31c290b5791 · Ajuste direto
A2 · Late Publication A9 · Price Overrun
€7,942 2014-08-29
Aquisição de 2 500 supositórios de Paracetamol 250 mg
PT · 1112190 · Ajuste Direto Regime G...
A9 · Price Overrun
€150 2014-07-01
TIROTROPINA ALFA
PT · 5514cb919cdbf4a96d68 · Ajuste direto
A2 · Late Publication A9 · Price Overrun +1
€19,752 2014-03-19
Overview
Total Value Won
€23,580,624,795
Contracts Won
7,813
Score 270380 · CRITICAL RISK
NIF
500134960
Country
PT
Directors & Officers

Personal data is pseudonymised for public access. Authenticate with a journalist token to view full names and NIFs.

  • A.J. [P-80b1]
    Gerente
    since 2012-06-11
  • A.D. [P-b42a]
    Gerente
    since 2014-03-13
  • E.Y. [P-6b36]
    Gerente
    since 2009-07-20
  • E.Y. [P-6b36]
    Gerente
    since 2013-05-06
  • E.Y. [P-6b36]
    Gerente
    since 2017-04-21
  • F.H. [P-552f]
    Gerente
    since 2022-09-19
  • H.P. [P-8f90]
    Gerente
    since 2022-09-19
  • J.C. [P-68bf]
    Gerente
    since 2013-05-06
  • L.M. [P-2cbf]
    Gerente
    since 2017-04-21
  • M.A. [P-5a28]
    Gerente
    since 2012-03-29
  • P.H. [P-715b]
    Vogal
    since 2008-10-08
  • P.H. [P-715b]
    Gerente
    since 2009-07-20
  • P.H. [P-715b]
    Gerente
    since 2010-06-18
  • R.G. [P-82e4]
    Gerente
    since 2012-10-08
  • S.J. [P-ba88]
    Gerente
    since 2015-05-25
  • A.N. [P-619a]
    Sócio
    since 2009-07-20
  • A.N. [P-619a]
    Sócio
    since 2012-03-29
  • S.A. [P-d154]
    Sócio
    since 2012-03-29
  • S.A. [P-d154]
    Sócio
    since 2017-01-26
  • S.F. [P-48a6]
    Sócio
    since 2019-05-31
  • S.A. [P-7997]
    Sócio
    since 2012-03-29
  • S.A. [P-7997]
    Sócio
    since 2017-01-26
  • S.A. [P-7997]
    Sócio
    since 2019-05-31
  • S.A. [P-66a2]
    Sócio
    since 2009-07-20
  • S.A. [P-23ed]
    Sócio
    since 2009-07-20
  • S.A. [P-77cb]
    Sócio
    since 2009-07-20
  • A.J. [P-80b1]
    Gerente
    2013-05-06 → 2015-03-12
  • A.M. [P-e9b6]
    Gerente
    2017-04-21 → 2018-06-20
  • A.M. [P-3895]
    Administrador
    until 2008-07-24
  • C.J. [P-f846]
    Gerente
    2014-03-13 → 2014-10-14
  • F.A. [P-a314]
    Gerente
    2015-03-12 → 2015-05-25
  • F.J. [P-1a2d]
    Gerente
    2018-06-21 → 2022-09-19
  • F.H. [P-9178]
    Gerente
    2009-07-20 → 2010-07-12
  • J.R. [P-2e21]
    Gerente
    2010-06-18 → 2012-05-22
  • M.A. [P-5a28]
    Gerente
    2013-05-06 → 2013-12-12
  • M.A. [P-8a48]
    Gerente
    2017-04-21 → 2022-09-19
  • O.M. [P-f83e]
    Gerente
    2010-07-12 → 2012-10-08
  • R.G. [P-82e4]
    Gerente
    2013-05-06 → 2014-03-13
Ownership & Registries

Beneficial ownership data (shareholders, directors, ultimate beneficial owners) is not yet imported. Links below open external public registries.

Registo Comercial (MJ) ↗ RCBE — Beneficial Ownership Register ↗

Full RCBE access requires judicial authentication (CJEU 2022 ruling limits public exposure).

Search in TED (EU procurement) ↗
Phase 7 — ownership layer planned